Site Map

Biometrics »

Develogen Announces Completion Of A Phase 1 Clinical Trial Of DG3173, A Novel Somatostatin Analogue For The Treatment Of Acromegaly

Wed, 8 Oct 2008 Similar Items Print Press Release Submissions »

Goettingen, Germany — DeveloGen AG, a privately held biopharmaceutical company developing novel therapeutics for the treatment of metabolic and endocrine diseases announced today that it has completed… Read »

 

Similar Items:
Bayer Reports Progress In Clinical Program For RiociguatBayer Reports Progress In Clinical Program For Riociguat
Addex PARKINSON’S Product Progressing In Early Clinical TrialsAddex PARKINSON’S Product Progressing In Early Clinical Trials
Oral Anticancer Drug CP-4126 Enters Clinical Phase I StudyOral Anticancer Drug CP-4126 Enters Clinical Phase I Study
Evotec Announces Phase I Initiation With P2X7 AntagonistEvotec Announces Phase I Initiation With P2X7 Antagonist
Genzyme Begins Enrollment In Post-marketing Study To Evaluate Use Of Low Dose Fabrazyme Treatment For Fabry DiseaseGenzyme Begins Enrollment In Post-marketing Study To Evaluate Use Of Low Dose Fabrazyme Treatment For Fabry Disease
Aeras And Crucell Announce Tb Vaccine Clinical Trial In Kenya; Promising Vaccine Candidate Advances To Phase Ii Safety Study In South AfricaAeras And Crucell Announce Tb Vaccine Clinical Trial In Kenya; Promising Vaccine Candidate Advances To Phase Ii Safety Study In South Africa
Abbott Announces Humira® (adalimumab) Approved In Japan For The Treatment Of Rheumatoid ArthritisAbbott Announces Humira® (adalimumab) Approved In Japan For The Treatment Of Rheumatoid Arthritis
Early Data Show Potential For Imatinib To Treat Life-threatening Form Of Pulmonary Artery DiseaseEarly Data Show Potential For Imatinib To Treat Life-threatening Form Of Pulmonary Artery Disease
Roche Announces Topline Outcomes For Avastin-tarceva Combination Study In Advanced Lung CancerRoche Announces Topline Outcomes For Avastin-tarceva Combination Study In Advanced Lung Cancer
Researchers To Evaluate A Once-daily Investigational Dose Of Raltegravir, MERCK’S Integrase Inhibitor, In An Investigational Population, Patients Previously Untreated For HIV-1Researchers To Evaluate A Once-daily Investigational Dose Of Raltegravir, MERCK’S Integrase Inhibitor, In An Investigational Population, Patients Previously Untreated For HIV-1